Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.61 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.61 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL61382 | 1.00 | ALDH1A1 (0.63) | ALDH1A1HTTTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL24710084 | 0.87 | ALDH1A1 (0.61) | ALDH1A1HTTTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL30133383 | 0.87 | ALDH1A1 (0.61) | ALDH1A1HTTTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL5197237 | 0.86 | ALDH1A1 (0.61) | ALDH1A1HTTTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL15482833 | 0.86 | KMT2A (0.66) | ALDH1A1HTTTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL15074699 | 0.84 | KMT2A (0.51) | ALDH1A1HTTTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL29871655 | 0.82 | LMNA (0.47) | ALDH1A1HTTTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL10289743 | 0.82 | CTSD (0.49) | ALDH1A1HTTKMT2AMEN1LMNA | |
| SCHEMBL20990440 | 0.82 | ALDH1A1 (0.74) | ALDH1A1HTTKMT2AMEN1LMNA | |
| SCHEMBL659023 | 0.82 | ALDH1A1 (0.74) | ALDH1A1HTTKMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338591-B2 | 3-aryl-5,6-disubstituted pyridazines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-12-25 | — | — | US | disclosed |
| EP-1745024-B1 | 1-ARYL-4-SUBSTITUTED ISOQUINOLINES | NOVARTIS INT PHARM LTD (BM) | 2012-04-25 | — | — | EP | disclosed |
| EP-1565452-B1 | 3-SUBSTITUTED-6-ARYL PYRIDINES AS LIGANDS OF C5A RECEPTORS | NOVARTIS INT PHARM LTD (BM) | 2012-04-04 | — | — | EP | disclosed |
| US-8129395-B2 | 4,5-disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-03-06 | — | — | US | disclosed |
| US-20110281837-A1 | 3-SUBSTITUTED-6-ARYL PYRIDINES | HUTCHINSON ALAN J (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110160187-A1 | 3-aryl-5,6-disubstituted pyridazines | NEUROGEN CORPORATION (US) | 2011-06-30 | — | — | US | disclosed |
| US-7915288-B2 | 1-aryl-4-substituted isoquinolines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-03-29 | — | — | US | disclosed |
| US-7863454-B2 | 3-substituted-6-aryl pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-01-04 | — | — | US | disclosed |
| US-20100022516-A1 | 4,5-Disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2010-01-28 | — | — | US | disclosed |
| EP-1745033-A4 | 4,5-DISUBSTITUTED-2-ARYL PYRIMIDINES | NEUROGEN CORP (US) | 2009-08-26 | — | — | EP | disclosed |
| EP-1745024-A4 | 1-ARYL-4-SUBSTITUTED ISOQUINOLINES | NEUROGEN CORP (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20070249665-A1 | 1-aryl-4-substituted isoquinolines | NEUROGEN CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| EP-1745039-A2 | 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES | Neurogen Corporation (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1745024-A1 | 1-ARYL-4-SUBSTITUTED ISOQUINOLINES | NEUROGEN CORPORATION (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1745033-A2 | 4,5-DISUBSTITUTED-2-ARYL PYRIMIDINES | NEUROGEN CORPORATION (US) | 2007-01-24 | — | — | EP | disclosed |
| WO-2006004589-A2 | 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES | NEUROGEN CORPORATION (US) | 2006-01-12 | — | — | WO | disclosed |
| US-20050277654-A1 | 4,5-Disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2005-12-15 | — | — | US | disclosed |
| WO-2005110416-A2 | 4,5-DISUBSTITUTED-2-ARYL PYRIMIDINES | NEUROGEN CORPORATION (US) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005110991-A1 | 1-ARYL-4-SUBSTITUTED ISOQUINOLINES | NEUROGEN CORPORATION (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20040158067-A1 | 3-substituted-6-aryl pyridines | NEUROGEN CORPORATION | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281837-A1 | 3-SUBSTITUTED-6-ARYL PYRIDINES | C3AR1, C5AR1, C5AR2 | ALDH1A1 1966/4885HTT 4493/4885TAS1R3 636/4885 |
| US-20050277654-A1 | 4,5-Disubstituted-2-aryl pyrimidines | C5AR2, C3AR1, C5AR1 | ALDH1A1 1616/4885HTT 4546/4885TAS1R3 1154/4885 |
| US-20100022516-A1 | 4,5-Disubstituted-2-aryl pyrimidines | C5AR2, C5AR1, C3AR1 | ALDH1A1 1684/4885HTT 4501/4885TAS1R3 1115/4885 |
| US-20070249665-A1 | 1-aryl-4-substituted isoquinolines | C3AR1, C5AR1, C5AR2 | ALDH1A1 1164/4885HTT 3970/4885TAS1R3 907/4885 |
| US-20110160187-A1 | 3-aryl-5,6-disubstituted pyridazines | MMP25, MMP9, MMP3 | ALDH1A1 403/4885HTT 3469/4885TAS1R3 2759/4885 |
| US-20040158067-A1 | 3-substituted-6-aryl pyridines | C3AR1, C5AR1, C5AR2 | ALDH1A1 1444/4885HTT 4549/4885TAS1R3 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.